Literature DB >> 15986459

Effect of the covalent modification of horseradish peroxidase with poly(ethylene glycol) on the activity and stability upon encapsulation in polyester microspheres.

Wasfi Al-Azzam1, Emil A Pastrana, Brian King, Jessica Méndez, Kai Griebenow.   

Abstract

Encapsulation of proteins in polyester microspheres by coacervation methods frequently causes protein inactivation and aggregation. Furthermore, an often-substantial amount of the encapsulated proteins is released within the first 24 h from the microspheres. To overcome these problems poly(ethylene glycol) (PEG) was employed as excipient and protein-modifying agent. The model protein horseradish peroxidase (HRP) was chemically modified or co-lyophilized with PEG of differing molecular weights, namely PEG(5000), PEG(20000), and PEG(40000). The lyophilized preparations were encapsulated in poly(D,L-lactide-co-glycolic) acid (PLGA) microspheres by a coacervation method. Covalent modification of HRP with PEG increased the encapsulation efficiency (EE) from 83% to about 100% while PEG when used as an excipient reduced the EE. Encapsulation caused aggregation of ca. 5% of non-modified HRP and the residual specific activity was only 57%. Covalent modification with PEG reduced HRP aggregation to less than 1% and improved its residual activity to more than 95%. When PEG was used as excipient similar results were found with respect to a reduction in encapsulation-induced aggregation, but no more than 80% of residual activity was obtained even for the best formulation after encapsulation. It was also found that covalent modification of HRP with PEG substantially reduced the unwanted initial "burst" release observed during the initial 24 h of in vitro release from about 70% to 23%. Furthermore, HRP activity and stability were also improved during in vitro release for HRP-PEG conjugates. The data show that covalent modification of proteins with PEG might be useful to improve protein stability during coacervation encapsulation and subsequent release as well as to increase EE and reduce the burst release. (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986459     DOI: 10.1002/jps.20407

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Improved enzyme activity and stability in polymer microspheres by encapsulation of protein nanospheres.

Authors:  Brenda L Montalvo-Ortiz; Brian Sosa; Kai Griebenow
Journal:  AAPS PharmSciTech       Date:  2012-04-27       Impact factor: 3.246

2.  Vancomycin- and Poly(simvastatin)-Loaded Scaffolds with Time-Dependent Development of Porosity.

Authors:  A D Thilanga Liyanage; Alexander J Chen; David A Puleo; F Joseph Halcomb
Journal:  ACS Appl Bio Mater       Date:  2019-05-17

3.  Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study.

Authors:  Rahul S Rajan; Tiansheng Li; Mohini Aras; Christopher Sloey; Weston Sutherland; Hiromi Arai; Robert Briddell; Olaf Kinstler; Alexis M K Lueras; Yu Zhang; Heather Yeghnazar; Michael Treuheit; David N Brems
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

4.  Loading PEG-catalase into filamentous and spherical polymer nanocarriers.

Authors:  Eric A Simone; Thomas D Dziubla; Evguenia Arguiri; Vanessa Vardon; Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Vladimir R Muzykantov
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

5.  Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2.

Authors:  Marian H Hettiaratchi; Tobias Miller; Johnna S Temenoff; Robert E Guldberg; Todd C McDevitt
Journal:  Biomaterials       Date:  2014-05-28       Impact factor: 12.479

6.  Pharmaceutically modified subtilisins withstand acidic conditions and effectively degrade gluten in vivo.

Authors:  Ghassan Darwish; Eva J Helmerhorst; Detlef Schuppan; Frank G Oppenheim; Guoxian Wei
Journal:  Sci Rep       Date:  2019-05-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.